Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Drug Name | LAG525 |
Trade Name | |
Synonyms | LAG-525|Leramilimab |
Drug Descriptions |
LAG525 (Leramilimab) is a monoclonal antibody that targets LAG3 and blocks interaction with MHC class II molecules, leading to enhanced T-cell response to tumor cells and decreased tumor growth (NCI Drug Dictionary). |
DrugClasses | Immune Checkpoint Inhibitor 98 LAG3 Antibody 12 |
CAS Registry Number | 2137049-37-5 |
NCIT ID | C122683 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Canakinumab + LAG525 + Spartalizumab | Canakinumab LAG525 Spartalizumab | 0 | 1 |
Capmatinib + LAG525 + Spartalizumab | Capmatinib LAG525 Spartalizumab | 0 | 1 |
Carboplatin + LAG525 | Carboplatin LAG525 | 0 | 1 |
Carboplatin + LAG525 + Spartalizumab | Carboplatin LAG525 Spartalizumab | 0 | 1 |
LAG525 | LAG525 | 0 | 2 |
LAG525 + MCS110 + Spartalizumab | LAG525 MCS110 Spartalizumab | 0 | 1 |
LAG525 + PBF-509 + Spartalizumab | LAG525 PBF-509 Spartalizumab | 0 | 1 |
LAG525 + Spartalizumab | LAG525 Spartalizumab | 0 | 2 |